StockData

BioNTech vs Moderna

BNTX and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNTX and MRNA compare

BioNTech grew revenue faster over the last twelve months (4.3% versus −27.6% for Moderna).

BioNTech keeps more of each dollar of sales as profit, with a net margin of −39.6% compared with −141% at Moderna.

Moderna scores higher on the StockData Score (5 against 3 for BioNTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNTXMRNA
Size and price
Market cap–$82.6B
Share price$84.86$206.80
Change, 1 year−17.7%735%
Change, 5 years−75.6%−37.3%
Beta (5Y)1.15−0.29
Employees5004,700
StockData Score
Total score35 (better)
Valuation score00
Growth score11
Performance score11
Health score13 (better)
Dividend score00
Valuation
P/S–37.1×
P/B–12.2×
FCF yield–−1.5%
Fair value–$32.48
Margin of safety–−537%
Growth
Revenue growth (TTM)4.3% (better)−27.6%
Revenue growth, 5Y average42.9% (better)19.3%
Profitability
Gross margin77.6% (better)23.4%
Operating margin−49.0% (better)−149%
Net margin−39.6% (better)−141%
FCF margin9.8% (better)−55.8%
Return on equity–−39.0%
Return on invested capital–−80.9%
Financial health
Debt / equity–0.09
Interest coverage−20.1×–
Current ratio7.54 (better)2.29
Altman Z-score–12.01
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions18.9%79.9%
Held by insiders58.2%5.6%
Insider net buying, 12 months−$89.8M−$81.6M (better)
Short interest, % of float–8.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.